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Cytomegalovirus (CMV) has highly evolved mechanisms for avoiding detection by the host immune system.
Recently, in the genomes of human and primate CMV, a novel gene comprising segments of noncontiguous
open reading frames was identified and found to have limited predicted homology to endogenous cellular
interleukin-10 (IL-10). Here we investigate the biological activities of the CMV IL-10-like gene product and
show it to possess potent immunosuppressive properties. Both purified bacterium-derived recombinant CMV
IL-10 and CMV IL-10 expressed in supernatants of human cells were found to inhibit proliferation of
mitogen-stimulated peripheral blood mononuclear cells (PBMCs), with specific activity comparable to that of
recombinant human IL-10. In addition, CMV IL-10 expressed from human cells inhibited cytokine synthesis,
as treatment of stimulated PBMCs and monocytes with CMV IL-10 led to a marked decrease in production of
proinflammatory cytokines. Finally, CMV IL-10 was observed to decrease cell surface expression of both major
histocompatibility complex (MHC) class I and class II molecules, while conversely increasing expression of the
nonclassical MHC allele HLA-G. These results demonstrate for the first time that CMV has a biologically
active IL-10 homolog that may contribute to immune evasion during virus infection.
homology to cellular IL-10. In contrast, viral IL-10 homologs
have been identified in the genomes of Epstein-Barr virus
(EBV) (12), equine herpesvirus 2 (27), and the orf virus of the
Poxviridae family (7), but these are encoded as contiguous
ORFs generating proteins with 67 to 90% identity to human
IL-10. EBV-encoded BCRF1, the first viral IL-10 homolog
described, displays many of the activities of human IL-10, such
as cytokine synthesis inhibition and macrophage deactivation
(5, 12). Despite the extensive sequence homology with human
IL-10, EBV IL-10 does not stimulate proliferation of B cells
(as human IL-10 does), suggesting that viral IL-10 homologs
may retain only a subset of human IL-10 activities that are
advantageous for the virus.
IL-10 is a pleiotropic cytokine that is important in the regulation of the immune response. IL-10 was initially identified
as a product of murine Th2 cells that inhibited the proliferation and effector activity of Th1 cells, although stimulatory
effects on the proliferation of B cells and mast cells have been
reported (19). In addition to inhibiting cytokine production,
IL-10 has been shown to inhibit expression of MHC class II
and adhesion molecules on monocytes, contributing to suppression of the Th1 type response (4, 5). The functional domains of human IL-10 have been mapped to defined regions;
amino acids 8 to 16 were found to induce proliferation of mast
cells, while a nine-amino-acid region at the carboxy terminus
has cytokine synthesis inhibitory function (8). EBV IL-10 is
partially conserved at the carboxy terminus (six of nine residues) and has been shown to inhibit cytokine synthesis (12).
The HCMV IL-10 homolog has only one conserved residue in
this region, and the RhCMV IL-10 sequence has no amino acid
homology with either rhesus cellular IL-10 or human IL-10 in
this domain, suggesting that the human and primate CMV

Cytomegalovirus (CMV) is a widespread human pathogen
with the ability to persist as a lifelong latent infection. Successful coexistence with its host is facilitated by numerous mechanisms that the virus has acquired for modulating the host
immune system (11). The US2, US3, US6, and US11 gene
products interfere with antigen processing and presentation,
resulting in reduced major histocompatibility complex (MHC)
class I presentation (1). In addition, the UL18 gene product is
an MHC class I homolog that may facilitate evasion of natural
killer cells (2). An ␣-chemokine homolog (encoded by UL146)
that is chemotactic for neutrophils (22) and a ␤-chemokine
receptor (US28 gene product) that binds human chemokines
have also been identified (20). Most recently, a homolog of the
potent immune modulator interleukin-10 (IL-10) was discovered in the genomes of human CMV (HCMV) and rhesus
macaque CMV (RhCMV) (13, 15).
The HCMV and RhCMV IL-10 proteins are distinctive in
that they have only 27 and 25% identity with their host cellular
IL-10 proteins, respectively. They are encoded from noncontiguous stretches in the viral genome, including open reading
frame (ORF) UL111A and adjacent intergenic areas. The
CMV gene structures are distinct from those of the host IL-10
genes in that the HCMV IL-10 gene has two introns and the
RhCMV IL-10 gene has three introns (compared to four in
human and rhesus cellular IL-10 genes). Although the HCMV
genome (strain AD169) was sequenced several years ago (3),
the existence of CMV IL-10 has remained cryptic until recently, probably because of the unusual gene structure and low
* Corresponding author. Mailing address: ChemoCentryx, 1539 Industrial Rd., San Carlos, CA 94070. Phone: (650) 632-2902. Fax: (650)
632-2910. E-mail: tschall@chemocentryx.com.
† Present address: Ceretek, LLC, Alameda, CA 94502.
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IL-10 homologs may have different activities than human IL10.
Despite the low homology of the CMV IL-10-like proteins
with their cellular counterparts, recent evidence suggests that
HCMV IL-10 may bind to the cellular human IL-10 receptor
(13). However, no experimental evidence has previously demonstrated the biological activity or potency of this molecule.
Therefore, we examined whether the CMV IL-10 proteins
were biologically active gene products with properties that
might be favorable to CMV immune evasion. To investigate
this, we developed in vitro assays utilizing the IL-10 homologs
from the HCMV Towne strain (ATCC VR977) and RhCMV
strain 68.1 (ATCC VR677). To demonstrate interspecies conservation of activities we expressed both CMV IL-10 genes as
recombinant proteins in human cells. In addition purified recombinant HCMV IL-10 was produced in bacteria to elucidate
the potency of this molecule with respect to recombinant human IL-10. Here we describe the activities of these viral proteins. CMV IL-10 expressed in human cells exhibited profound
inhibition of human and rhesus peripheral blood mononuclear
cell (PBMC) proliferation and decreased the production of
proinflammatory cytokines in PBMC and monocyte cultures.
In addition, CMV IL-10 induced down regulation of cell surface MHC class I and class II proteins on monocytes, while the
nonclassical MHC class I protein HLA-G was up regulated on
the same cells. Additionally purified recombinant bacteriumexpressed HCMV IL-10 demonstrated a specific activity comparable to that of recombinant human IL-10 in reduction of
mitogen-stimulated proliferation of PBMCs, and this activity
was inhibited by a monoclonal antibody to the human IL-10
receptor. These results demonstrate that CMV IL-10 possesses
many immunosuppressive properties that may interfere with
the host immune response.
MATERIALS AND METHODS
Cells. PBMCs were obtained from the peripheral blood of healthy rhesus
macaques by hypotonic lysis of red blood cells or from the buffy coats of cells
from healthy human donors by Ficoll density gradient centrifugation. PBMCs
were maintained in RPMI (HyClone) plus 10% fetal calf serum (FCS) (HyClone) and recombinant human IL-2 (10 ng/ml; R&D Systems). Monocytes were
purified from PBMCs with anti-CD14 microbeads (Miltenyi) and cultured in
RPMI plus 10% FCS.
Recombinant CMV IL-10 expression. Human embryonic kidney (HEK) 293
(ATCC CRL1573) cells were grown in DMEM (HyClone) plus 5% FCS and
transiently transfected with a myc/His-tagged expression vector containing either
the cDNA sequence of RhCMV IL-10 (pcDNA3.1 m/H-RhCMV IL-10) described previously (15) or the cDNA sequence of HCMV (Towne) IL-10
(pcDNA3.1 m/H-HCMV IL-10). Cells were transfected with Superfect transfection reagent according to the manufacturer’s instructions (Qiagen). Supernatants
were collected after 48 h and clarified by low-speed centrifugation, and protein
expression was verified by Western blotting with an anti-poly-His monoclonal
antibody (Invitrogen). Detection was via TMB membrane peroxidase substrate
(Kirkegaard & Perry Laboratories). Mock-conditioned medium was obtained
from cells transfected with the empty vector (pcDNA3.1-m/H; Invitrogen).
The concentration of CMV IL-10 present in culture supernatants was determined by comparison with a protein standard. Purified recombinant histidinetagged fractalkine (R&D Systems) of known concentration was serially diluted
and blotted alongside an equal volume of supernatant samples onto a nitrocellulose membrane using a standard dot blot apparatus. Once the samples dried,
the membrane was washed in Tris-buffered saline (TBS) and then blocked with
TBS–0.05% bovine serum albumin. The membrane was then incubated with
INDIA-Hisprobe-HRP detection reagent (Pierce Chemical Company) and
washed three times in TBS–0.5% Tween 20, and then horseradish peroxidase was
detected via West-Pico HRP detection reagent as per manufacturer’s instructions (Pierce Chemical Company) and exposure to Kodak X-Omat film. As
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fractalkine has a molecular mass of around 90 kDa and that of CMV IL-10 is
around 30 kDa, concentrations were adjusted by a factor of 3.0.
Recombinant HCMV IL-10. Purified recombinant HCMV IL-10 (strain
Towne) was obtained from R&D Systems.
Proliferation assays. Human or rhesus macaque PBMCs were plated in 96well culture dishes at a density of 105 cells per well and stimulated with phytohemagglutinin (PHA) (5 g/ml) or concanavalin A (Sigma) in the presence of
either 5 to 50% (vol/vol) supernatants from transfectants expressing CMV IL-10,
the control vector (mock), recombinant HCMV IL-10, or recombinant human
IL-10 (R&D Systems). Where indicated, CMV IL-10 was immunoprecipitated
from the transfectant supernatants by incubation with anti-poly-His antibody (10
g/ml) and protein A-Sepharose beads for 14 h at 4°C. In some assays monoclonal antibody to the human IL-10 receptor (R&D Systems) was included at 15
g/ml. The plates were incubated at 37°C for 72 h, and DNA synthesis was
determined by [3H]thymidine uptake (0.25 Ci/well; Amersham) during the last
18 h of culture.
Cytokine ELISA. Human PBMCs or positively selected CD14⫹ monocytes
were plated in 96-well culture dishes at a density of 105 cells per well and
stimulated with PHA or lipopolysaccharide (LPS) (Sigma) in the presence of
mock- or CMV IL-10-conditioned medium. After 48 h, supernatants were harvested and cytokine production was measured by sandwich enzyme-linked immunosorbent assay (ELISA). Briefly, 96-well microtiter plates (Nalge Nunc)
were coated with anticytokine capture antibody (4 g/ml; anti-alpha interferon
[IFN-␣], -tumor necrosis factor alpha [TNF-␣], -granulocyte-macrophage colony-stimulating factor [GM-CSF], -IL-1␣, or -IL-6 from R&D Systems) for 16 h
at 4°C. After blocking with 1% bovine serum albumin (in phosphate-buffered
saline), 100 l of culture supernatant was added. After washing, biotinylated
anticytokine antibodies (2 g/ml; R&D Systems) were added, followed by
streptavidin-horseradish peroxidase (Gibco BRL). Detection was via Genzyme
color reagents (Genzyme Diagnostics); the reaction was terminated with 50 l of
2 N HCl solution per well, and samples were read at 450 nm in a microplate
reader (Molecular Devices). Cytokine levels were determined by linear regression analysis using a standard curve.
Flow cytometry. Monocytes were stained with phycoerythrin-conjugated antibodies to CD54 (immunoglobulin G1 [IgG1]); HLA-DR (IgG2a); HLA-A, -B, or
-C (IgG1); or the appropriate isotype control (Pharmingen) and analyzed using
a FACScan device and CellQuest software (Becton Dickinson). Staining with
antibody 87G directed against HLA-G (14) was followed by incubation with goat
anti-mouse immunoglobulin–phycoerythrin secondary antibody.

RESULTS
CMV IL-10 inhibits PBMC proliferation. To elucidate the
scope of biological activities of CMV IL-10 and to examine
interspecies differences in these activities, recombinant CMV
IL-10 was generated in HEK 293 cells transfected with plasmid
DNA encoding a C-terminal myc/His epitope-tagged CMV
IL-10 protein from either RhCMV strain 68.1 or HCMV strain
Towne. Transfectant supernatants were harvested and examined by Western blotting with an antibody directed to the
C-terminal poly-His tag. Supernatants from RhCMV IL-10transfected cells were found to express a protein of 26 kDa, the
predicted size of the epitope-tagged CMV IL-10 (15), for at
least 48 h posttransfection (Fig. 1A). The HCMV IL-10 protein appeared as a 30- to 35-kDa protein, consistent with the
predicted size of the protein with glycosylation (13). The diffuse protein band seen for HCMV IL-10 probably results from
variability in the number of carbohydrate residues. In contrast,
the RhCMV IL-10 protein, which lacks the corresponding Nlinked glycosylation site, appeared as a distinct band (Fig. 1A),
suggesting that the RhCMV protein is not glycosylated. The
concentration of recombinant CMV IL-10 was determined by
comparison to an identically histidine-tagged protein (fractalkine), assessed in a dot blot assay. All preparations of CMV
IL-10 were reproducibly found to contain between 100 and 600
ng of IL-10/ml.
The effects of CMV IL-10 on PBMC proliferation in the
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FIG. 1. Supernatant CMV IL-10 inhibits PBMC proliferation. (A) Western blot analysis of supernatants from transfected HEK 293 cells with
an anti-poly-His antibody. Cells were transiently transfected with pcDNA3.1-m/H-RhCMV IL-10, pcDNA3.1-m/H-HCMV IL-10, or an empty
vector control (mock). MW, molecular weight marker (sizes at right, in thousands). (B) PBMCs from healthy human donors were stimulated with
PHA for 72 h in the presence of RhCMV IL-10 or mock supernatants. Proliferation was measured by [3H]thymidine uptake during the final 18 h
of culture. RhCMV IL-10 was immunoprecipitated from conditioned medium with an anti-poly-His antibody (CMV IL-10 ⫹ Ab). Error bars,
standard deviations. (C) PBMCs from nine human donors were tested for effects on proliferation in the presence of HCMV IL-10-conditioned
medium or recombinant human IL-10 (1 g/ml). Results are expressed as percent increase in proliferation relative to control cultures from the
same donor. The horizontal bar indicates mean change in proliferation for all donors.

absence of other virally produced factors was assessed using a
panel of mitogen-stimulated PBMCs from human and rhesus
macaque donors. Every donor, regardless of species, showed
marked inhibition of proliferation in the presence of RhCMV
IL-10. Due to the greater availability of human PBMC, results
for human PBMC are shown as representative throughout.

Mitogen-stimulated PBMC exhibited robust proliferation, but
this proliferation was inhibited in the presence of RhCMV
IL-10 (Fig. 1B). While conditioned media constituted 50% of
the total culture volume in these experiments, inhibition of
proliferation was observed in cultures containing as little as 5%
RhCMV IL-10-conditioned medium. Proliferation of cells cul-
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tured in the presence of the mock-conditioned medium was
not found to differ from that of cells cultured in fresh RPMI.
To confirm that the inhibitory activity was solely a province of
CMV IL-10, culture supernatants were depleted of RhCMV
IL-10 by adsorption with an antibody directed to the histidine
tag. This resulted in a near total restoration of PBMC proliferation to levels observed with mock medium (Fig. 1B). In the
representative experiment shown, RhCMV IL-10 inhibited the
proliferation of human PBMC; however, equivalent inhibition
of rhesus PBMC proliferation was also seen. Likewise, supernatant HCMV IL-10 was found to substantially reduce proliferation of human PBMC (data not shown), suggesting that
both HCMV and RhCMV IL-10 homologs can suppress the
replication of immune cells.
To compare this activity to that of the endogenous IL-10 a
bank of PBMC samples was stimulated in the presence of
HCMV IL-10 or recombinant human IL-10. While HCMV
IL-10 inhibited PBMC proliferation for all donors tested (57 to
91% inhibition), variability was observed with human IL-10
treatment. PBMC proliferation for four donors was inhibited
in the presence of recombinant human IL-10 at a concentration of 1 g/ml (16 to 81% inhibition), while four other donors
showed enhanced proliferation (increases of 24 to 194%) and
one donor showed modest enhancement. The differing effects
of recombinant human IL-10 on PBMC may reflect not only
variability among human donors but also the mixed population
of cells within the PBMC culture. It has been documented that
human IL-10 can have inhibitory effects on monocytes and
CD4⫹ T cells while having stimulatory effects on B cells and
CD8⫹ T cells (19); thus, increased proliferation of some
PBMC cultures could represent outgrowth of these cell types.
In contrast, HCMV IL-10 suppressed proliferation over a wide
range of concentrations on PBMC cultures from multiple donors. These data may suggest that HCMV IL-10 lacks some of
the stimulatory activities of human IL-10.
CMV IL-10 inhibits cytokine synthesis. The hallmark activity of human IL-10 is inhibition of cytokine synthesis; therefore, we examined whether CMV IL-10 would alter the level of
cytokine production in PBMC cultures. PHA-stimulated human PBMCs were cultured in the presence of mock-, HCMV
IL-10-, or RhCMV IL-10-conditioned medium. After 48 h, the
supernatants from these cultures were assayed for cytokine
levels by ELISA. While control PBMC cultures produced
IFN-␥ in response to PHA stimulation, cytokine levels were
decreased in cultures containing RhCMV IL-10 or HCMV
IL-10 (Fig. 2). IFN-␥ production was almost completely abolished in the presence of either viral cytokine. As an additional
control, PBMC cultures were treated with recombinant human
IL-10 (1 g/ml), which also dramatically inhibited cytokine
production. The results demonstrate that, like human IL-10,
HCMV and RhCMV IL-10 homologs can exert profound inhibition of proinflammatory cytokine production by human
leukocytes.
Because PBMC cultures represent a mixed population of
cells, we next examined the effects of CMV IL-10 on a homogenous cell population. Primary human monocytes were purified from PBMCs by positive selection with CD14 microbeads.
Flow cytometric analysis revealed the resulting cell population
to be ⬎99% CD14 positive (data not shown). Monocytes were
stimulated with LPS in the presence of mock- or CMV IL-10-
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FIG. 2. CMV IL-10 inhibits cytokine production by activated human PBMCs. PHA-stimulated PBMCs were incubated in the presence
of mock-, RhCMV IL-10-, or HCMV IL-10-conditioned medium or
recombinant human IL-10 (1 g/ml). Supernatants were harvested
after 48 h and assayed for IFN-␥ production by sandwich ELISA.

conditioned medium or recombinant human IL-10. Supernatants from these cultures were harvested after 48 h and assayed
for proinflammatory cytokines by ELISA. In LPS-stimulated
monocyte cultures, a robust dose-dependent production of IL1␣, IL-6, GM-CSF, and TNF-␣ was observed, and this production was greatly reduced in the presence of HCMV IL-10 or
recombinant human IL-10. (Fig. 3). Similar results were observed upon treatment of human monocytes with RhCMV
IL-10 (data not shown). Thus, CMV-encoded IL-10 has direct
suppressive effects on monocytes, causing a profound decrease
in the production of immunoregulatory cytokines.
Cell surface MHC expression is altered by CMV IL-10.
IL-10 has been reported to lead to decreased levels of MHC
class II molecules and ICAM-1 on monocytes (5, 31), a putative mechanism by which immune responses are modulated
and homeostasis is maintained. Decreased cellular surveillance
may also potentiate viral infection. Human LPS-stimulated
monocytes were first treated with RhCMV IL-10. Flow cytometric analysis showed that cell surface expression of ICAM-1
on LPS-stimulated monocytes was not significantly affected by
RhCMV IL-10 treatment (Fig. 4, left panels). In contrast, cell
surface levels of both MHC class I and class II antigens were
reduced on the entire cell population by incubation with
RhCMV IL-10 (Fig. 4, center panels). MHC class II levels
were decreased by RhCMV IL-10 treatment in every donor
tested, with the mean fluorescence intensity of MHC class II
staining for RhCMV IL-10 treated cells being nearly threefold
lower than that for cells treated with the mock-conditioned
medium for all donors. The effect of RhCMV IL-10 on monocyte MHC class I protein expression was more variable; decreased cell surface expression was observed in four of six
donors, while two of six donors were unaffected. This may
reflect donor variability or differences in cellular activation
states. Similar results were obtained following treatment with
HCMV IL-10 (data not shown). Overall, CMV IL-10 treat-
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FIG. 3. HCMV IL-10 inhibits expression of proinflammatory cytokines by human monocytes. Monocytes were stimulated with LPS and
incubated in the presence of mock- or HCMV IL-10-conditioned medium or recombinant human IL-10 (rhIL-10) (1 g/ml). Supernatants were
harvested after 48 h and assayed for IL-1␣, IL-6, GM-CSF, and TNF-␣ production by sandwich ELISA. Error bars, standard deviations.

ment was observed to lead to decreased cell surface expression
of both class I and class II MHC molecules on LPS stimulated
monocytes, a scenario that may contribute to viral escape from
immune surveillance.
Finally, we examined the ability of CMV IL-10 to influence
expression of nonclassical MHC antigens. HLA-G has been
observed to confer protection from natural killer cell-mediated
lysis (28), and human IL-10 has been linked to HLA-G up
regulation on monocytes and trophoblasts (18). Since other
CMV proteins have been implicated in the resistance of infected cells to NK cell lysis (11), we asked whether CMV IL-10
might play a role in evading detection by NK cells. Again cells
were treated with supernatants containing RhCMV IL-10. As
shown in Fig. 4, the intensity of HLA-G cell surface staining
was increased following RhCMV IL-10 treatment (right panels). Similar results were seen with HCMV IL-10-containing
supernatants. Up regulation of cell surface HLA-G expression
was seen in all donors tested. Thus, in contrast to the decreased
cell surface expression of classical MHC class I molecules
observed in the presence of CMV IL-10, levels of HLA-G
expression on monocytes were increased. The results demonstrate that CMV IL-10 modulates multiple aspects of the cell-

mediated immune response by effecting major changes in class
I and class II MHC expression.
Recombinant HCMV IL-10 functions through the IL-10 receptor. To more directly compare the activities of CMV IL-10
and human IL-10, purified recombinant HCMV IL-10 was
obtained (R&D Systems). Recombinant human or CMV IL-10
was serially diluted, and their effects on PHA-stimulated proliferation of PBMC were measured by tritium incorporation.
As with the CMV IL-10 supernatants, the recombinant HCMV
IL-10 had inhibitory effects on proliferation. Both molecules
significantly inhibited proliferation down to 10 to 100 pg/ml in
replicate assays (Fig. 5A and B), suggesting that the molecules
have a comparable specific activity in this assay.
To ascertain that the inhibitory activity was modulated specifically through the IL-10 receptor, the assay was repeated in
the presence of neutralizing antibody to the human IL-10 receptor. Monoclonal anti-human IL-10 receptor antibody markedly increased proliferation of PBMCs at all assay points (Fig.
5C and D, gray bars) compared to parallel samples with no
antibody (Fig. 5C and D, black bars), probably through neutralizing endogenous IL-10 produced by the cells during the
incubation period. This effect of anti-IL-10 receptor antibodies

1290

SPENCER ET AL.

J. VIROL.

FIG. 4. MHC expression is altered by RhCMV IL-10. Flow cytometric analysis of LPS-stimulated monocytes cultured in the presence of mockor RhCMV IL-10-conditioned medium. After 48 h the cells were stained for cell surface expression of CD54 (ICAM), MHC class I (HLA-A, -B,
and -C), MHC class II (HLA-DR), and the nonclassical class I MHC molecule HLA-G. Filled histograms represent staining with the indicated
antibody; open histograms indicate isotype controls. The mean fluorescence intensity is indicated in the upper right corner of each plot.

on PBMC proliferation is a typical observation in assays of this
nature (M. Howard, personal communication). However the
antibody also neutralized the effects of the presumably greater
quantity of exogenously provided recombinant human IL-10
(Fig. 5C) and recombinant HCMV IL-10 (Fig. 5D). Only high
levels of recombinant protein were able to inhibit proliferation
of PBMCs compared to the RPMI control. These results demonstrate that recombinant HCMV IL-10 has strong antiproliferative activity, comparable to that of human IL-10, and mediates its activity through the human IL-10 receptor.
DISCUSSION
Immunosuppression is a well-documented feature of acute
CMV infection (16). Although these effects have in part been
attributed to virus-induced dysfunction of the monocyte/macrophage population, it has been difficult to define factors that
contribute to systemic immunosuppression due to the size and
complexity of the CMV genome. In this report, we demonstrate that the HCMV- and RhCMV-encoded IL-10 homologs
have a broad spectrum of immunosuppressive properties. The
CMV IL-10 proteins, despite their low homology to endogenous cellular IL-10 proteins, can inhibit PBMC proliferation,
suppress cytokine production, and down regulate the antigenpresenting and accessory cell functions of monocytes. Hence,
CMV IL-10 may contribute to CMV-induced immunosuppression and be an important factor in viral pathogenesis.
IL-10 is an important regulator of inflammation; the essential role of this cytokine in limiting the immune response is
evidenced by chronic inflammatory disease in mice lacking the
IL-10 gene (24). Furthermore, the production of IL-10 by
tumor cells for evasion of immune surveillance has been well
documented (9). The observation that CMV IL-10 inhibits
immune proliferation and cytokine production indicates that
this protein likely plays a major role in the interaction of the
virus with the host immune system. Previous work has shown
that the CMV IL-10 gene is expressed in HCMV-infected cells

(13) and in RhCMV-infected cells, where it was shown to be an
early transcript expressed abundantly during infection (15).
Polyclonal antiserum raised against the RhCMV IL-10 protein
recognizes a 26-kDa band in infected cell lysates, demonstrating that the protein is expressed during infection. Furthermore,
serum from chronically infected rhesus macaques was found to
recognize the same 26-kDa protein from infected cell lysates as
well as the recombinantly expressed epitope-tagged protein
(15), suggesting that CMV IL-10 is a target of the host immune
response. Given the previous findings, the antiproliferative activity of CMV IL-10 observed here in vitro could reflect a
relevant in vivo modulation of the host immune system important for viral pathogenesis.
Interestingly, results from our studies suggest that CMV
IL-10 has the capacity to impair the proliferation of a wide
range of cell types at concentrations ranging from 25 up to 250
ng/ml. In contrast, human IL-10 was observed to have both
inhibitory and stimulatory effects on proliferation of cells from
various donors. Stimulation of PBMC proliferation was observed over a range of concentrations of recombinant human
IL-10, from 1 ng to 1 g/ml (data not shown). The stimulatory
activities of human IL-10 on some cell types, including CD8⫹
T cells, have been documented (19, 29). It is interesting to
speculate that this may represent a key difference in activities,
as CD8⫹ T-cell-mediated immunity is crucial in control of
CMV infection both in murine models and in humans following bone marrow transplantation (25, 26). Although the levels
of CMV IL-10 produced in vivo during infection have yet to be
determined, the extensive inhibitory effects of CMV IL-10 on
PBMC suggest that the viral homolog may have evolved functions distinct from its cellular counterpart that are beneficial to
virus replication, perhaps underscored by the sequence divergence within functionally important domains.
Despite differences in antiproliferative activity, levels of inhibition of cytokine production were comparable and profound
for both CMV IL-10 and human IL-10. Treatment with CMV
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FIG. 5. Recombinant HCMV IL-10 inhibits PBMC proliferation. PBMCs from healthy human donors were stimulated with PHA for 72 h in
the presence of serial dilutions of recombinant HCMV IL-10 (B and D [black bars]) or recombinant human IL-10 (A and C [black bars]).
Proliferation was measured by [3H]thymidine uptake during the final 18 h of culture. Activity of recombinant proteins was abolished by the
presence of monoclonal anti-human IL-10 receptor antibody at 15 g/ml (C and D [gray bars]). Error bars, standard deviations.

IL-10 virtually abolished production of cytokines by activated
PBMCs and monocytes, as did treatment with recombinant
human IL-10. In vivo studies with murine CMV have shown
IFN-␥ to be crucial for the antiviral response (10); thus, the
reduction in cytokine production effected by CMV IL-10 may
result in delayed activation and/or recruitment of immune cells
to the sites of virus infection, favoring virus replication and
dissemination. Also striking was the effect of CMV IL-10 on
cell surface levels of MHC class II antigen in our system. MHC
class II expression is induced by IFN-␥; therefore, down modulation of class II by CMV IL-10 could be via direct action of
the viral cytokine or through indirect effects resulting from
IFN-␥ suppression. Interestingly, HCMV has been reported to
interfere with transcription of class II genes through disruption
of the Jak/Stat signaling pathway, although the factors mediating this event have not been defined (17). Our observations
demonstrate that CMV IL-10 induces reduction in class II
MHC expression on monocytes, and this correlates with the
finding that CMV IL-10 binds to the cellular IL-10 receptor
and induces signal transduction that leads to Jak/Stat signaling
(13). Human IL-10 is known to activate Stat 1 and Stat 3,
suppressing a number of IFN-␥ inducible genes, including class
II MHC genes (6). Murine CMV has been reported to cause
down regulation of class II MHC antigen expression through

induction of endogenous IL-10 at early times following infection (23); these same activities are likely carried out directly by
the HCMV and RhCMV IL-10 homologs during infection. In
addition, elevated levels of human IL-10 in plasma have been
reported during CMV infection in some renal transplant recipients (21), suggesting further redundancy in efforts of the
virus to attain replicative advantage by modulation of the host
immune response.
While interference with class II MHC is an effective mechanism for suppression of cell-mediated immunity, we have also
observed a role for CMV IL-10 in down modulation of MHC
class I on monocytes. CMV encodes several proteins (US2,
US3, US6, and US11) that interfere with the class I antigen
processing and presentation pathway (11). We have shown that
CMV IL-10 causes decreased surface expression of class I
MHC, a function that has also been demonstrated for cellular
and EBV IL-10 (31, 32). While the mechanism for class I down
modulation has yet to be explored, it is possible that CMV
IL-10 is acting through the regulation of transcription, a checkpoint upstream of the actions of other CMV encoded class I
interference proteins.
The down regulation of classical MHC class I molecules
observed in the presence of CMV IL-10 is in direct contrast to
the effects on the nonclassical MHC protein HLA-G. HLA-G
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is important in feto-maternal tolerance by inhibiting lysis of
fetal cells by maternal NK cells (28). Expression of HLA-G on
trophoblasts and monocytes has been linked to IL-10 (18). Our
results demonstrate that CMV IL-10 can increase expression
of HLA-G, suggesting that CMV has evolved a novel mechanism for subversion of NK cell reactivity. Another CMV ORF,
UL18, encodes a class I homolog that may confer protection
from NK cell lysis (2) and recently gpUL40 has been implicated in the up regulation of HLA-E, another nonclassical
MHC protein (30). Given the multiple strategies for subversion of the class I antigen presentation system, it would not be
surprising if CMV had acquired several different mechanisms
for avoiding NK cell lysis. Additional investigations are under
way to examine in detail the regulation of HLA-G by CMV
IL-10.
Evasion of immune detection is a central feature of a successful latent virus infection. We demonstrate that the HCMVand RhCMV-encoded IL-10 homologs have a broad spectrum
of immunosuppressive properties that may be utilized to escape immune detection. Characterization of biological functions conserved by CMV IL-10 contributes to our knowledge
of virus-host interactions and also provides greater understanding of the regulation of the host immune system.
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